This project aims to evaluate the effectiveness of the rodent-targeted vaccine (RTV) developed by US Biologic in reducing the prevalence of Borrelia burgdorferi, the causative agent of Lyme disease, infections in questing Ixodes scapularis nymphs. By targeting the rodents that act as reservoirs for the Lyme disease pathogen, the study will determine whether the vaccine significantly lowers the infection rate of ticks that may use these animals as hosts. This assessment is crucial for understanding how well the RTV can contribute to controlling Lyme disease by decreasing the risk of transmission from infected ticks.